United Kingdom Immunofluorescence Assay Market Insight
Published: 30 July 2026 | Report Format: Electronic (PDF) | Author: Sanket and Pranali
The United Kingdom Immunofluorescence Assay Market is projected to grow at a CAGR of 6.7% from 2025 to 2035, driven by the rising prevalence of autoimmune and infectious diseases, increasing demand for rapid laboratory diagnostics, expanding clinical research, and growing adoption of advanced fluorescence-based testing technologies
United Kingdom Immunofluorescence Assay Market Forecasts to 2035
- The United Kingdom Immunofluorescence Assay Market Size was estimated at USD 0.31 Billion in 2025.
- The market is expected to grow at a CAGR of 6.7% from 2025 to 2035.
- The United Kingdom Immunofluorescence Assay Market Size is expected to reach USD 0.59 Billion by 2035.
Notable Insights for the United Kingdom Immunofluorescence Assay Market
- Segmentation: Based on product type, reagents & kits, antibodies, instruments, and consumables collectively accounted for approximately 71% of the market share in 2025, supported by increasing diagnostic testing volumes and routine laboratory applications.
- Segmentation: Based on application, autoimmune diseases, infectious diseases, oncology diagnostics, and research applications represented nearly 74% of total market revenue in 2025, reflecting growing clinical adoption of immunofluorescence-based diagnostic techniques.
- Thermo Fisher Scientific Inc. and Danaher Corporation reported revenues of approximately USD 42.88 billion and USD 23.88 billion in 2024, reflecting their strong positions in immunodiagnostics, life science research, and advanced laboratory testing solutions.
- Abbott Laboratories and Bio-Rad Laboratories, Inc. continue strengthening their diagnostics portfolios across the United Kingdom. Abbott generated approximately USD 42.0 billion, while Bio-Rad reported around USD 2.58 billion in revenue during 2024, supporting continued innovation in immunofluorescence assay technologies.
Download the eBook (ToC)
Why Buy This Report
- Provides a comprehensive assessment of the United Kingdom Immunofluorescence Assay Market, covering diagnostic technologies, assay products, laboratory workflows, clinical applications, and long-term market opportunities.
- Delivers valuable insights into reagent innovations, fluorescence microscopy systems, automated immunofluorescence analyzers, digital pathology integration, and evolving diagnostic practices across hospitals, reference laboratories, and research institutes.
- Assists diagnostic manufacturers, biotechnology companies, clinical laboratories, healthcare providers, distributors, investors, and policymakers in identifying emerging opportunities, evaluating competitive dynamics, and supporting strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Immunofluorescence Assay Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Immunofluorescence Assay Market
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Merck KGaA
- Revvity, Inc. (PerkinElmer)
- Siemens Healthineers AG
- F. Hoffmann-La Roche Ltd.
- EUROIMMUN Medizinische Labordiagnostika AG
- bioMérieux SA.
Recent Developments:
- In March 2025, Thermo Fisher Scientific launched an enhanced ImmunoFluor Autoimmune Detection Panel for clinical laboratories in the United Kingdom, enabling improved multiplex fluorescence imaging, higher diagnostic accuracy, and faster autoimmune disease identification.
- In October 2024, Abbott Laboratories and University College London Hospitals (UCLH) expanded their collaboration to advance immunofluorescence-based diagnostic research, supporting earlier detection of autoimmune disorders and improving laboratory workflow efficiency across NHS facilities.
Market Segmentation:
United Kingdom Immunofluorescence Assay Market, By Product
- Reagents & Kits
- Antibodies
- Instruments
- Consumables
United Kingdom Immunofluorescence Assay Market, By Technique
- Direct Immunofluorescence
- Indirect Immunofluorescence
United Kingdom Immunofluorescence Assay Market, By Application
- Autoimmune Diseases
- Infectious Diseases
- Oncology
- Cardiovascular Diseases
- Endocrine Disorders
- Neurological Disorders
- Research Applications
- Others
United Kingdom Immunofluorescence Assay Market, By End User
- Hospitals
- Clinical Diagnostic Laboratories
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Others
United Kingdom Immunofluorescence Assay Market, By Region
- England
- Scotland
- Wales
- Northern Ireland
Expert Views:
The United Kingdom Immunofluorescence Assay Market is expected to experience healthy growth through 2035, supported by increasing demand for highly sensitive diagnostic techniques, expanding autoimmune disease screening, and continuous advancements in laboratory automation. Greater adoption of multiplex immunofluorescence technologies, digital pathology platforms, and AI-assisted image analysis is improving diagnostic precision and laboratory productivity. As leading diagnostic manufacturers continue introducing innovative assay platforms and strengthening collaborations with healthcare providers and research institutions, the market is anticipated to create significant opportunities for clinical laboratories, biotechnology companies, diagnostic solution providers, and healthcare organizations across the United Kingdom.
Author: Sanket and Pranali By Decisions Advisors and Consulting